There are currently thirteen FDA-approved Antibody-Drug Conjugates (ADCs) for cancer treatment, and this promising technology is now showing potential in treating autoimmune diseases in humans. However, due to poor cross-species reactivity between therapeutic antibodies and their targets, uncovering the potential of these therapeutics has proven complicated when using conventional mouse models.

In this webinar, Director of Scientific Engagement at GemPharmatech, Dr. Jun Wang, and President of BioRay Pharmaceutical, Dr. Gang Chen, discussed how humanized mice help overcome the limitations of conventional mouse models and provide insights on how to use these models to evaluate the therapeutic potential of ADCs.

Key Topics Include:

- Advantages of using humanized mouse models to evaluate ADCs

- Applications of humanized mice to evaluate ADCs in autoimmune disease models

- The design and screening of the Linker-Payloads of Bioray’s Immune modulating ADC (ImADC^TM)

Speakers:

Jun Wang, PhD

Director of Scientific Engagement

GemPharmatech

Dr. Jun Wang has over 15 years of experience in biomedical research. Prior to joining GemPharmatech, he served as an Associate Director of Research at Explora Biolabs/Charles River. He has extensive experience with genetically engineered mouse models for drug discovery in various therapeutic areas. Dr. Wang holds a Ph.D. in Developmental Neurobiology from the City of Hope and received his postdoctoral training in pediatric brain cancer research from the Sanford Burnham Prebys Medical Discovery Institute.

Gang Chen, PhD

President

Bioray Pharmaceutical

Dr. Gang Chen is the head of Bioray Pharmaceutical and leads a team of scientists developing novel ADCs for cancer and autoimmune diseases. He has over 25 years of experience in the field of antibody engineering and ADC development. Dr. Chen holds a Ph.D. in Biochemistry from the University of Texas at Austin.